CD274 and neoplasm: In addition, the strategy of using genetically engineered probiotics to produce nano‐antibodies targeting PD‐L1 and cytotoxic T lymphocyte‐associated antigen‐4 (CTLA‐4) to help T‐cells attack tumor cells has shown excellent results in cancers with a weak response to immunotherapy [52].